🇺🇸 FDA
Pipeline program

UX007

UX007G-CL301

Phase 3 small_molecule terminated

Quick answer

UX007 for Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 2 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials